Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.34 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.34 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.34 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.34 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.34 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 5/20 | 0.33 |
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | PNLIP | P16233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31677877 | 0.95 | SLC6A1 (0.34) | SLC6A1PLA2G2ASLC6A11PLA2G10PLA2G1B | |
| SCHEMBL31059240 | 0.91 | PLA2G2A (0.33) | SLC6A1PLA2G2ASLC6A11PLA2G10PLA2G1B | |
| SCHEMBL31678146 | 0.89 | PLA2G2A (0.36) | SLC6A1PLA2G2ASLC6A11PLA2G10PLA2G1B | |
| SCHEMBL30338217 | 0.88 | L3MBTL1 (0.37) | SLC6A1PLA2G2ASLC6A11PLA2G10PLA2G1B | |
| SCHEMBL31677916 | 0.83 | L3MBTL1 (0.36) | SLC6A1SLC6A11MEN1KMT2AHDAC6 | |
| SCHEMBL30976149 | 0.83 | PLA2G2A (0.35) | PLA2G2APLA2G10PLA2G1BPLA2G5MEN1 | |
| SCHEMBL30976245 | 0.82 | PLA2G2A (0.37) | PLA2G2APLA2G10PLA2G1BPLA2G5MEN1 | |
| SCHEMBL30976129 | 0.82 | PLA2G2A (0.37) | PLA2G2APLA2G10PLA2G1BPLA2G5MEN1 | |
| SCHEMBL30976214 | 0.82 | PLA2G2A (0.37) | PLA2G2APLA2G10PLA2G1BPLA2G5MEN1 | |
| SCHEMBL30976095 | 0.82 | PLA2G2A (0.37) | PLA2G2APLA2G10PLA2G1BPLA2G5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250268828-A1 | Lipid Nanoparticle Compositions for Delivering Circular Polynucleotides | ORNA THERAPEUTICS, INC. | 2025-08-28 | — | — | US | disclosed |
| EP-4408825-A1 | LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING CIRCULAR POLYNUCLEOTIDES | Orna Therapeutics, Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| WO-2023056033-A1 | LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING CIRCULAR POLYNUCLEOTIDES | ORNA THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268828-A1 | Lipid Nanoparticle Compositions for Delivering Circular Polynucleotides | ABCB4, CETP, HDLBP | SLC6A1 4639/4885PLA2G2A 109/4885SLC6A11 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.